A complex of platinum and human transferrin has been formed by appropriately combining apotransferrin (metal free protein) and potassiumchloroplatinate (K2PtCl4). Atomic absorption spectroscopy indicated that both primary bind sites on the protein participated in the complex. Electron paramagnetic resonance (EPR) examination showed that the bound platinum was not paramagnetic, and thus it is highly probable that the Pt ion is in the +2 oxidation state. The results suggest a possible mechanism for physiological distribution of third-transition-series metals.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0006-3061(78)80006-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MOF scaffold for anchoring platinum-nickel nanoparticles with enhanced oxidase-like activity to improve lateral flow immunoassay diagnosis.
Biosens Bioelectron
January 2025
School of Chemistry and Chemical Engineering, Yangzhou University, Yangzhou, China.
Noble metal nanoparticles have attracted tremendous attention as the promising signal reporters for catalytic-colorimetric lateral flow immunoassay (LFIA). However, it remains great challenges for improving their stability and catalytic activity. Herein, first, a kind of porphyrinic based metal-organic framework (MOF) was used as a carrier for loading platinum (Pt) nanoparticles to avoid its aggregation.
View Article and Find Full Text PDFReal-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants.
Cancer Med
February 2025
Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
Introduction: Pancreatic cancer arising in the context of BRCA predisposition may benefit from poly(ADP-ribose) polymerase inhibitors. We analyzed real-world data on the impact of olaparib on survival in metastatic pancreatic cancer patients harboring germline BRCA mutations in Italy, where olaparib is not reimbursed for this indication.
Methods: Clinico/pathological data of pancreatic cancer patients with documented BRCA1-2 germline pathogenic variants who had received first-line chemotherapy for metastatic disease were collected from 23 Italian oncology departments and the impact of olaparib exposure on overall survival (OS) was analyzed.
Mechanisms of Copper-Induced Autophagy and Links with Human Diseases.
Pharmaceuticals (Basel)
January 2025
School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
As a structural and catalytic cofactor, copper is involved in many biological pathways and is required for the biochemistry of all living organisms. However, excess intracellular copper can induce cell death due to its potential to catalyze the generation of reactive oxygen species, thus copper homeostasis is strictly regulated. And the deficiency or accumulation of intracellular copper is connected with various pathological conditions.
View Article and Find Full Text PDFRuthenium(II) Complex with 1-Hydroxy-9,10-Anthraquinone Inhibits Cell Cycle Progression at G0/G1 and Induces Apoptosis in Melanoma Cells.
Pharmaceuticals (Basel)
January 2025
Instituto de Química, Universidade Federal de Alfenas (UNIFAL-MG), Alfenas 37130-000, MG, Brazil.
Background: Melanoma is the most aggressive and lethal skin cancer that affects thousands of people worldwide. Ruthenium complexes have shown promising results as cancer chemotherapeutics, offering several advantages over platinum drugs, such as potent efficacy, low toxicity, and less drug resistance. Additionally, anthraquinone derivatives have broad therapeutic applications, including melanoma.
View Article and Find Full Text PDFOnvansertib and Navitoclax Combination as a New Therapeutic Option for Mucinous Ovarian Carcinoma.
Int J Mol Sci
January 2025
Laboratory of Gynecological Preclinical Oncology, Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
Mucinous epithelial ovarian cancer (mEOC) is a rare subtype of epithelial ovarian cancer, characterized by poor responses to standard platinum-based chemotherapy. Polo-like kinase 1 (PLK1) is a key regulator of mitosis and cell cycle progression and its inhibition has been recently identified as a target in mEOC. In this study, we aimed to identify further therapeutic targets in mEOC using a CRISPR/Cas9 library targeting 3015 genes, with and without treatment with onvansertib, a PLK1 inhibitor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!